Category Archives: – Pharma

Insurance companies are not paying for Repatha and Praluent

Posted on December 15, 2018 by admin

Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

Posted on December 1, 2018 by admin

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

Posted on September 1, 2018 by admin

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

Posted on September 1, 2018 by admin

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Is President Trump on amphetamines? (Yes, he is)

Posted on February 28, 2018 by admin

Update January 16, 2018- by Steven E. Greer, MD President Trump’s doctor confirms my diagnosis made in the story below, which was that the slurred

Posted in - Opinion, - Pharma, - Policy, FDA, Internal Medicine, Neurology, Primary care medicine, Rehab | Leave a comment

Bending the cost curve of cancer care

Posted on February 26, 2018 by admin

May 25, 2011- Since the approval of Genentech’s costly Avastin in 2004, prominent oncologists have warned that

Posted in - Biotech, - Pharma, CMS, Oncology, VCU | Leave a comment

NBC begins alarming new series to promote the diagnosis of “mental illness” in children

Posted on February 24, 2018 by admin

December 11, 2017

Posted in - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Neurology, Neurosurgery, NIH, Pediatrics, Primary care medicine, Psychology Psychiatry, Rehab | Leave a comment

Oh my god, I have a disease!

Posted on February 21, 2018 by admin

March 21, 2014- This DTC TV drug ad medicalizing a non-disease really struck us as egregious

Posted in - Pharma, Congress, FDA | Leave a comment

The serious adverse events caused by antipsychotics

Posted on January 13, 2018 by admin

February 1, 2014

Posted in - Pharma, FDA | Leave a comment

Steve Bannon and the epidemic of Baby Boomers with mental illness

Posted on January 5, 2018 by admin

January 5, 2017- by Steven E. Greer, MD President Trump made news yesterday by issuing a statement firing back at Steve Bannon for allegations

Posted in - Opinion, - Pharma, - Policy, Geriatrics, Neurology, Psychology Psychiatry, Rehab | Leave a comment

The super shady methods of pricing generic drugs in America: case study- Sildenafil

Posted on January 4, 2018 by admin

May 15, 2016- by Steven E. Greer, MD The last I read, Teva and Mylan were not supposed to launch their approved generic of Viagra (sildenafil)

Posted in - Generics, - Opinion, - Pharma, CMS, Congress, FDA | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

Posted on January 2, 2018 by admin

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

CDER Director Janet Woodcock on new drug safety strategies

Posted on January 2, 2018 by admin

November 16, 2010- by Steven E. Greer, MD We interviewed Dr. Janet Woodcock, long-time Director of CDER, the FDA center responsible

Posted in - Pharma, FDA | Leave a comment

A disease called ‘childhood’

Posted on December 11, 2017 by admin

March 31, 2013- by Dr. Allen Frances Do 1 in 5 NYC preteens really suffer a mental woe? A psychiatry expert argues we’re overdiagnosing —

Posted in - Pharma, - Policy, Neurology, Pediatrics, Psychology Psychiatry | Leave a comment

How ADHD became such a prevalent condition

Posted on December 11, 2017 by admin

October 7, 2009- interviewed by Steven E. Greer Authors of “ADHD: medicating children”, Rick Mayes and Catherine Bagwell, discuss the history of ADHD

Posted in - Pharma, - Reviews, books, devices, Congress, Neurology, Neurosurgery, Pediatrics, Primary care medicine, Psychology Psychiatry | Leave a comment

This could be the best interview ever aired on Fox Business

Posted on November 15, 2017 by admin

August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

Posted on September 9, 2017 by admin

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Biggest Healthcare Stories of 2016

Posted on December 26, 2016 by admin

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

Posted on November 1, 2016 by admin

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

The Biggest stories of 2015

Posted on October 20, 2016 by admin

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment